Wednesday, July 30, 2014 6:43:39 PM
"To date, a single site has recruited all subjects and subject data that will constitute the subject population for the interim analysis," said Dr. Kirby. "Data from the interim analysis that will be reported at #C4CT will include N=34 healthy normal and N=10 Alzheimer's disease subjects. We are continuing enrollment at the three clinical sites that recently completed their internal Institutional Review Board (IRB) process and are now enrolling for LP-002. We very much look forward to sharing the interim results tomorrow with the community."
Best investment this year, AMBS!
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM